CJC-1295 with DAC vs Pitavastatin
Well Studied vs FDA Approved
synergistic Mechanism-based · 60% Pitavastatin helps manage estrogen conversion from CJC-1295 with DAC. This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 with DAC Pitavastatin
Weight 3,647.28 Da 421.46 Da
Half-life 6-8 days ~12 hours
Chain 30 amino acids —
Type GHRH analog with DAC Synthetic statin (C25H24FNO4)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Pitavastatin
1-4 mg/day / Once daily
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Research Evidence
CJC-1295 with DAC Pitavastatin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.